Page 211 - ebook HCC

EASL HCC SUMMITHCC SUMMIT
GENEV
PROGRAMME
209
208 PROGRAMME AND ABSTRACTSAND ABSTRACTS GENEVA, SWITZERLANDA, SWITZERLAND EASL 209
208
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
FEBRUAR
Poster Board Number C9
PERSONALIZED SORAFENIB THERAPY FOR
HEPATOCELLULAR CARCINOMA

Giuseppe Cabibbo , Massimo Lavarone , Marcello Maida , Arezia Di Martino , The median survival was 21.6 months (mo) in treated group A versus 15.7 mo in untreated
2
1
1
1
Emanuele Orlando , Claudio Zavaglia , Antonio Grieco , Erica Villa , Fabio Piscaglia , group A, 12.9 mo in treated group C versus 7.3 mo in untreated group C, and 4.9 mo in
1
4
5
6
3
Vito Di Marco , Massimo Colombo , Antonio Craxì , Calogero Cammà 1 treated group B versus 7 mo in untreated group B.
1
1
2
1 Section of Gastroenterology, DIBIMIS, Policlinico P. Giaccone, University of Palermo,
2
Palermo, 1st Division of Gastroenterology, Fondazione IRCCS Ca‘ Granda Maggiore Conclusions: Individual variables of HCC patients treated with sorafenib have a more
3
Hospital, University of Milan, Struttura Complessa di Epatologia e Gastroenterologia, accurate prediction of survival than the stages Barcelona Clinic Liver Cancer classification.
Azienda Ospedaliera Niguarda Ca’ Granda, Milan, Institute of Internal Medicine, School
4
5
of Medicine, Catholic University of the Sacred Heart, Rome, Dipartimento di Medicina
Interna, UO Gastroenterologia, Universita` di Modena & Reggio Emilia, Modena,
6 Division of Internal Medicine, Department of Digestive Disease and Internal Medicine,
General and University S. Orsola-Malpighi Hospital, Bologna, Italy
Corresponding author’s e-mail: marcello.maida@hotmail.it
Introduction: Due to the wide heterogeneity of intermediate/advanced hepatocellular
carcinoma (HCC), a confident prediction of survival in individual patients treated with
sorafenib is lacking.
Aims: By identification of individual predictor of survival, we sought to establish an
individualized survival prediction for HCC patients treated with sorafenib.
Results: The survival curves of patients included in the SOFIA study (Iavarone M et al.
CLINICAL POSTER ABSTRACTS multivariate analysis of the SOFIA study.Six groups of patients were evaluated. Survival CLINICAL POSTER ABSTRACTS
Hepatology. 2011) and in a previous published cohort of untreated patients (Cabibbo
G et al. World J Hepatol. 2012) were derived from predictors of death identified from
curves of patients with Performance Status (PS) 0, without macrovascular invasion or
distant metastases, namely extra-hepatic spread (ES) and mainly treated with half-dose
of sorafenib (better patient profile – treated group A), patients with PS 1 or 2, with ES
and mainly treated with full-dose of sorafenib (worst patient profile – treated group B),
patients not included in group A or B (intermediate patient profile – treated group C),
were compared with survival curves of untreated patients with PS 0, without ES (better
patient profile – untreated group A), untreated patients with PS 1 or 2, with ES (worst
patient profile – untreated group B), and untreated patients not included in group A or B
(intermediate patient profile – untreated group C).